An Phase III Study, Multicenter ，Randomized Controlled Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.
Conditions: Bladder Cancer Interventions: Drug: Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib; Drug: Tislelizumab, Cisplatin, Gemcitabine Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Babytam vs Babyexe in Post-menopausal Women at High Risk for Breast Cancer.
Conditions: Breast Cancer Interventions: Drug: Tamoxifen 10 MG; Drug: Exemestane 25 MG Sponsors: Andrea DeCensi; Dana-Farber/Brigham and Women ' s Cancer Center; Herbert Irving Comprehensive Cancer Center; Istituto Europeo di Oncologia; Breast Cancer Research Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Patient Reported Outcomes (PROs) in Anal Cancer Patient Treated by Intensity Modulated Radiotherapy (IMRT).
Conditions: Anal Cancer Patients Sponsors: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Phase Ib/II Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma
Conditions: Bladder Cancer Interventions: Drug: Tislelizumab combined with two predefined dose groups of palbociclib; Drug: RP2D dose Of Tislelizumab combined with palbociclib was selected for phase II clinical trial. Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding
Conditions: Endometrial Carcinoma Interventions: Other: Non-Interventional Study Sponsors: Mayo Clinic Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer
Conditions: Predictive Cancer Model; Pathologic Complete Response Interventions: Other: Medical examination Sponsors: Sixth Affiliated Hospital, Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Esophageal Self-expandable Metal Stent for Malignant Strictures: a Safety and Efficacy Study
Conditions: Oesophageal Cancer Interventions: Device: Esophageal self-expandable metal stent Sponsors: Erasmus Medical Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
Conditions: Non-Small Cell Lung Cancer; PDL1 Negative Non-Small Cell Lung Cancer (NSCLC) Interventions: Drug: Pembrolizumab; Drug: Carboplatin; Drug: Paclitaxel; Drug: Pemetrexed; Drug: Nivolumab; Drug: Ipilimumab Sponsors: University of Alabama at Birmingham Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers
Conditions: MMR-D/MSI-H Colorectal Cancers Interventions: Drug: Niraparib; Drug: Dostarlimab Sponsors: Ibrahim Halil Sahin; GlaxoSmithKline Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer
Conditions: Triple Negative Breast Neoplasms Interventions: Drug: Abemaciclib; Drug: Bicalutamide Sponsors: Universitaire Ziekenhuizen KU Leuven; Kom Op Tegen Kanker; Eli Lilly and Company; Teva Pharma Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
Conditions: Recurrent Ovarian Cancer; Folate Receptor-Alpha Positive Interventions: Drug: Mirvetuximab Soravtansine; Drug: Lubricating Eye Drops; Drug: Prednisolone acetate ophthalmic suspension 1% eye drops; Drug: Brimonidine tartrate ophthalmic solution eye drops Sponsors: ImmunoGen, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab
Conditions: Endometrial Cancer; Recurrent Endometrial Cancer; TP53 Interventions: Drug: Abemaciclib; Drug: Letrozole; Drug: Pembrolizumab Sponsors: Dana-Farber Cancer Institute; Eli Lilly and Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
A Study to Assess the Ability of Stereotactic Radiotherapy to Restore the Efficacy of Immunotherapy in Patients With Metastatic Cancer.
Conditions: Metastatic Cancer Interventions: Radiation: Stereotactic Radiotherapy Sponsors: Elsan Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
Conditions: ALK-positive Non-small Cell Lung Cancer; Real World Study Interventions: Drug: Lorlatinib Sponsors: Sichuan Cancer Hospital and Research Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
Molecular Analyses to Identify Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer
Conditions: Breast Cancer Interventions: Drug: Aromatase inhibitors or tamoxifen Sponsors: Medical College of Wisconsin Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
